S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:CFMS

Conformis - CFMS Stock Forecast, Price & News

$2.80
+0.32 (+12.90%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.43
$2.80
50-Day Range
$0.07
$2.80
52-Week Range
$1.20
$23.57
Volume
108,840 shs
Average Volume
232,420 shs
Market Capitalization
$21.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Conformis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.7% Upside
$4.50 Price Target
Short Interest
Healthy
1.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Conformis in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.32) to ($5.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

232nd out of 1,047 stocks

Surgical Appliances & Supplies Industry

9th out of 23 stocks

CFMS stock logo

About Conformis (NASDAQ:CFMS) Stock

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Stock News Headlines

Conformis (NASDAQ:CFMS) Coverage Initiated at StockNews.com
Conformis Announces Full Commercial Launch of Imprint™
Conformis, Inc. Effects 1-for-25 Reverse Stock Split
Conformis Reports Third Quarter 2022 Financial Results
Conformis, Inc. (CFMS)
Here's Why ConforMIS (CFMS) Stock is Tanking Today
See More Headlines
Receive CFMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

CFMS Company Calendar

Last Earnings
11/02/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFMS
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+60.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-2,410,000.00
Net Margins
-104.46%
Pretax Margin
-104.45%

Debt

Sales & Book Value

Annual Sales
$99.86 million
Cash Flow
$0.28 per share
Book Value
$8.14 per share

Miscellaneous

Free Float
7,239,000
Market Cap
$21.06 million
Optionable
Not Optionable
Beta
1.14

Key Executives

  • Mr. Mark A. AugustiMr. Mark A. Augusti (Age 56)
    CEO, Pres & Director
    Comp: $1.22M
  • Mr. Robert S HoweMr. Robert S Howe (Age 52)
    CFO & Treasurer
    Comp: $524.91k
  • Mr. Michael Fillion
    Chief Operating Officer
  • Ms. Denise E. Pedulla J.D. (Age 62)
    M.P.H., Chief Legal Officer & Corp. Sec.
  • Mr. Farzin Khaghani
    VP of U.S. Marketing
  • Ms. Allison Baker
    Director of HR
  • Eric Rickenbach
    Sr. VP of US Sales
  • Mr. Terrance Wong
    Sr. VP of Engineering & Regulatory
  • Ms. Erin Henry (Age 37)
    Corp. Controller
  • Ms. Christine Desrochers
    Corp. Controller













CFMS Stock - Frequently Asked Questions

Should I buy or sell Conformis stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFMS shares.
View CFMS analyst ratings
or view top-rated stocks.

What is Conformis' stock price forecast for 2023?

2 equities research analysts have issued 12-month price objectives for Conformis' shares. Their CFMS share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price.
View analysts price targets for CFMS
or view top-rated stocks among Wall Street analysts.

How have CFMS shares performed in 2022?

Conformis' stock was trading at $0.7610 on January 1st, 2022. Since then, CFMS shares have increased by 267.9% and is now trading at $2.80.
View the best growth stocks for 2022 here
.

Are investors shorting Conformis?

Conformis saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 71,800 shares, a drop of 73.5% from the October 31st total of 271,100 shares. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the shares of the company are short sold.
View Conformis' Short Interest
.

When is Conformis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our CFMS earnings forecast
.

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) posted its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The medical instruments supplier earned $13.78 million during the quarter, compared to analysts' expectations of $13.89 million. Conformis had a negative trailing twelve-month return on equity of 78.14% and a negative net margin of 104.46%.

What guidance has Conformis issued on next quarter's earnings?

Conformis issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.00 million-$14.00 million, compared to the consensus revenue estimate of $15.99 million.

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Conformis' stock symbol?

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Who are Conformis' major shareholders?

Conformis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (98.28%), Renaissance Technologies LLC (63.37%), Granite Point Capital Management L.P. (0.82%), MYDA Advisors LLC (0.37%) and Bank of New York Mellon Corp (4.89%). Insiders that own company stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti and Robert S Howe.
View institutional ownership trends
.

How do I buy shares of Conformis?

Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conformis' stock price today?

One share of CFMS stock can currently be purchased for approximately $2.80.

How much money does Conformis make?

Conformis (NASDAQ:CFMS) has a market capitalization of $21.05 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($8.75) on an earnings per share basis.

How many employees does Conformis have?

The company employs 310 workers across the globe.

How can I contact Conformis?

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.

This page (NASDAQ:CFMS) was last updated on 12/1/2022 by MarketBeat.com Staff